JOURNAL ARTICLE

Lilly's Obesity Drug Sales Rise 60% in India Amid Rising Demand.

  • Published In: Bloomberg.com, 2025. P. N.PAG 1 of 3

  • Database: Business Source Ultimate 2 of 3

  • Authored By: Sanjay, Satviki 3 of 3

Abstract

The article focuses on the significant increase in sales of Eli Lilly & Co.'s weight-loss and diabetes drug Mounjaro in India, which rose by 60% in May compared to April. The company generated approximately 126 million rupees ($1.5 million) in sales, with the 5 mg version seeing a notable increase in demand. The rising sales highlight the growing need for anti-obesity solutions in India, where obesity and diabetes are prevalent, affecting around 100 million people each. Additionally, Biocon Ltd. has received approval for Liraglutide, a generic version of Novo Nordisk's Victoza, indicating a competitive market for diabetes and obesity treatments in the country. [Extracted from the article]

Additional Information

  • Source:Bloomberg.com. 2025/06, pN.PAG
  • Document Type:Article
  • Subject Area:Health and Medicine
  • Publication Date:2025
  • Accession Number:185785370
  • Copyright Statement:Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.